Newborn screening for G6PD deficiency--why is it important for India?

Area of Science:

• Public Health
• Preventive Medicine
• Neonatal Care

Background:

• Neonatal screening is a key 21st-century public health initiative, widely adopted in developed nations.
• The Asia-Pacific region has a history of neonatal screening, notably G6PD screening in Singapore since 1965, which significantly reduced kernicterus.
• India currently lacks a government-funded national neonatal screening program, though private hospitals conduct targeted screenings.

Observation:

• The Indian Council of Medical Research is actively involved, with a task force and resources available for healthcare providers.
• Current practices in India involve private hospitals screening for region-specific neonatal disorders.
• The study underscores the need for widespread screening initiatives.

Findings:

• Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency screening is identified as a high priority for public health initiatives in India.
• The study provides evidence supporting the implementation of G6PD screening for the Indian population.

Implications:

• Implementing widespread G6PD screening can prevent severe neonatal complications and improve child health outcomes in India.
• This research supports the development of a national neonatal screening policy in India.
• Public health strategies should prioritize genetic disorder screening for newborns.